Search research articles
Contact Us
Filters
Showing results (141-150 of 188) with videos related to
Page
of 19
Sort By:
JCO Precision Oncology
|
February 14, 2024
Sunitinib in Patients With Breast Cancer With <i>FGFR1</i> or <i>FGFR2</i> Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Carmen J Calfa, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 19, 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I Daud, Jedd D Wolchok, Caroline Robert, et al.
The New England Journal of Medicine
|
August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Richard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.
Nature
|
November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
Caroline Robert, Wen-Jen Hwu, Omid Hamid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2018
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Journal for Immunotherapy of Cancer
|
May 8, 2021
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
Ahmad A Tarhini, Ni Kang, Sandra J Lee, et al.
Cancer
|
April 24, 2026
Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies
Tae Min Kim, Stephen K Williamson, Kyriakos P Papadopoulos, et al.
Nature Medicine
|
September 24, 2025
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
Georgina V Long, Nitya Nair, Daniel Marbach, et al.
Page
of 19
Search research articles
Search
Showing results (141-150 of 188) with videos related to
Sort By:
Page
of 19
JCO Precision Oncology
|
February 14, 2024
Sunitinib in Patients With Breast Cancer With <i>FGFR1</i> or <i>FGFR2</i> Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Carmen J Calfa, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 19, 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I Daud, Jedd D Wolchok, Caroline Robert, et al.
The New England Journal of Medicine
|
August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Richard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.
Nature
|
November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
Caroline Robert, Wen-Jen Hwu, Omid Hamid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2018
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Journal for Immunotherapy of Cancer
|
May 8, 2021
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
Ahmad A Tarhini, Ni Kang, Sandra J Lee, et al.
Cancer
|
April 24, 2026
Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies
Tae Min Kim, Stephen K Williamson, Kyriakos P Papadopoulos, et al.
Nature Medicine
|
September 24, 2025
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
Georgina V Long, Nitya Nair, Daniel Marbach, et al.
Page
of 19